[AGN] Allergan plc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 96.6 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 198.87 Change: 4.89 (2.52%)
Ext. hours: Change: 0 (0%)

chart AGN

Refresh chart

Strongest Trends Summary For AGN

AGN is in the long-term up 623% in 19 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well

Fundamental Ratios
Shares Outstanding395.56 M EPS EPS Growth - 4 Quarters115.47% EPS Growth - Q/Q75.5%
EPS Growth - Y/Y58.22% Sales Growth - 4 Quarters 16.06% Sales Growth - Q/Q5.14% P/E
P/E To EPS Growth0.57 P/S13.35 P/BV12.46 Price/Cash Per Share19.45
Price/Free Cash Flow57.37 ROA12.28% ROE19.66% ROI14.05%
Current Ratio4.41 Quick Ratio4.22 Long Term Debt/Equity0.39 Debt Ratio0.2
Gross Margin88.36% Operating Margin27.76% Net Profit Margin21.06% Dividend Payout Ratio-3.91%
Dividend Yield-0.06%
Fundamental Data
Cash From Financing Activities Cash From Investing Activities183.4 M Cash From Operating Activities144.6 M Gross Profit1.7 B
Net Profit694.2 M Operating Profit626.7 M Total Assets12.42 B Total Current Assets6.87 B
Total Current Liabilities1.56 B Total Debt2.09 B Total Liabilities4.66 B Total Revenue1.91 B
Technical Data
High 52 week254.35 Low 52 week163.58 Last close181.33 Last change0.94%
RSI76.15 Average true range4 Beta0.66 Volume3.21 M
Simple moving average 20 days5.72% Simple moving average 50 days5.79% Simple moving average 200 days-14.33%
Performance Data
Performance Week2.38% Performance Month6.1% Performance Quart-2.72% Performance Half-26.68%
Performance Year-14.39% Performance Year-to-date10.85% Volatility daily1.51% Volatility weekly3.37%
Volatility monthly6.91% Volatility yearly23.95% Relative Volume226.12% Average Volume3.42 M
New High New Low


2019-09-17 16:15:00 | Announcement under the Irish Takeover Rules: Relevant Securities in Issue - September 17, 2019

2019-09-17 15:30:43 | Could Algernon Pharmaceuticals Inc.'s CNSX:AGN Investor Composition Influence The Stock Price?

2019-09-17 07:30:00 | Allergan Announces Commencement of Mailing of Proxy Statement

2019-09-16 17:50:09 | Allergan AGN Dips More Than Broader Markets: What You Should Know

2019-09-16 09:01:09 | AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's euro notes; stable outlook

2019-09-13 11:08:03 | Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

2019-09-13 09:46:01 | Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others

2019-09-12 19:25:34 | Seth Klarman's Favorite Health Care Stocks

2019-09-12 18:22:56 | Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

2019-09-12 16:09:27 | Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade

2019-09-12 11:47:00 | Buy AbbVie Stock, Because Its Deal for Allergan Just Might Work, Analyst Says

2019-09-11 06:01:10 | Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe

2019-09-10 17:45:09 | Allergan AGN Outpaces Stock Market Gains: What You Should Know

2019-09-10 16:36:00 | Allergan Shareholder Meetings Scheduled for October 14, 2019

2019-09-09 11:33:03 | The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers

2019-09-09 09:19:12 | U.S. judge denies bid to dismiss claim opioids are a public nuisance

2019-09-09 07:30:00 | Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular Wet Age-related Macular Degeneration

2019-09-06 15:07:07 | ETFs Poised to Benefit from Gene Editing Revolution

2019-09-06 13:29:56 | UPDATE 1-Mallinckrodt to pay $24 mln in cash to settle opioid lawsuits with two Ohio counties

2019-09-06 11:36:03 | Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs

2019-09-05 16:51:07 | 3 Special Situations Gurus Are Buying

2019-09-05 10:35:02 | Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease

2019-09-05 09:31:01 | Allergan AGN Up 1.8% Since Last Earnings Report: Can It Continue?

2019-09-05 03:10:00 | [video]Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

2019-09-04 17:50:09 | Allergan AGN Outpaces Stock Market Gains: What You Should Know

2019-09-04 16:22:39 | Why The Opioid Epidemic Just Got More Complicated For Generic Pharmas

2019-09-04 10:31:02 | Ardelyx ARDX Gains on Tenapanor's Success in Pivotal Study

2019-09-03 07:30:00 | Allergan Receives FDA Approval of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula

2019-09-02 09:41:01 | Allergan Settles Ahead of Multi-District Opioid Litigation

2019-08-30 10:03:00 | Allergan Settles to Get Out Of First Big Opioid Trial

2019-08-30 09:57:00 | It’s Not All Bad News for Generic-Drug Companies. Sales Rose in July.

2019-08-30 08:00:12 | Will Opioid Litigation Take its Toll on Pharma Companies?

2019-08-30 07:09:00 | Allergan settles with 2 Ohio plaintiffs in federal opioid litigation

2019-08-30 07:00:00 | Allergan Announces Settlement with Two Ohio Plaintiffs in Federal Opioid Litigation

2019-08-30 05:39:00 | [video]Allergan Reaches Settlement With Ohio Plaintiffs in Federal Opioid Litigation

2019-08-28 16:29:15 | What Purdue's Rumored Deal Means For Other Opioid-Tied Pharmas

2019-08-27 14:03:00 | Should You Buy AbbVie for the Dividend?

2019-08-27 11:01:03 | J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case

2019-08-23 10:36:02 | Amgen Presents Positive Data From Rituxan Biosimilar Study

2019-08-23 10:15:02 | J&J's JNJ Opioid Lawsuit Verdict in Oklahoma Due Next Week

2019-08-23 04:59:24 | Hedge Funds Pile Into Health Care

2019-08-22 09:00:00 | Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® Rituximab

2019-08-21 16:15:54 | Opioid Epidemic: Will Pharmas Scramble To Settle As Landmark Case Looms?

2019-08-21 13:38:05 | Endo Up on Settlement of a Few Cases Related to Opioid Drugs

2019-08-21 13:11:35 | Goldman Warns Hedge Fund Outperformance Holds Crowding Risk

2019-08-21 07:15:00 | AbbVie Stock Slipped to a New Low, and One Exec Scooped Up Shares

2019-08-20 12:20:08 | Endo, Allergan could avoid trial with opioid settlements

2019-08-20 11:06:00 | Buy AbbVie Stock Because You ‘Can’t Ignore’ How Cheap It Is

2019-08-20 10:15:11 | Endo, Allergan could avoid trial with Ohio over opioid crisis

2019-08-20 09:44:01 | Here's Why Allergan is Outperforming Its Industry Of Late